AR104174A1 - Oxadiazoles sustituidos con deuterio - Google Patents

Oxadiazoles sustituidos con deuterio

Info

Publication number
AR104174A1
AR104174A1 ARP160100894A ARP160100894A AR104174A1 AR 104174 A1 AR104174 A1 AR 104174A1 AR P160100894 A ARP160100894 A AR P160100894A AR P160100894 A ARP160100894 A AR P160100894A AR 104174 A1 AR104174 A1 AR 104174A1
Authority
AR
Argentina
Prior art keywords
oxadiazols
deuterio
replaced
deuterium
deuterated
Prior art date
Application number
ARP160100894A
Other languages
English (en)
Inventor
Chakma Justin
Zhang Chengzhi
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AR104174A1 publication Critical patent/AR104174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen moduladores deuterados de los receptores S1P1 de fórmula (1), sus composiciones farmacéuticas y sus procedimientos de uso, en donde R¹ - R²⁴ se seleccionan de modo independiente del grupo que consiste en hidrógeno y deuterio y al menos uno de R¹ - R²⁴ es deuterio o contiene deuterio.
ARP160100894A 2015-04-06 2016-04-01 Oxadiazoles sustituidos con deuterio AR104174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143489P 2015-04-06 2015-04-06

Publications (1)

Publication Number Publication Date
AR104174A1 true AR104174A1 (es) 2017-07-05

Family

ID=55697512

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100894A AR104174A1 (es) 2015-04-06 2016-04-01 Oxadiazoles sustituidos con deuterio

Country Status (8)

Country Link
US (1) US20180016244A1 (es)
EP (1) EP3280703A1 (es)
AR (1) AR104174A1 (es)
AU (1) AU2016246398A1 (es)
CA (1) CA2981743A1 (es)
IL (1) IL254679A0 (es)
TW (1) TW201636336A (es)
WO (1) WO2016164180A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
CN109219597A (zh) * 2016-06-14 2019-01-15 苏州科睿思制药有限公司 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
US11028060B2 (en) 2016-08-19 2021-06-08 Receptos Llc Crystalline forms of ozanimod and processes for preparation thereof
WO2018050091A1 (zh) 2016-09-14 2018-03-22 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
CN106674053A (zh) * 2016-12-27 2017-05-17 苏州山青竹生物医药有限公司 一种3‑氰基‑4‑异丙氧基苯甲酸甲酯的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
EP3677575A4 (en) 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
CN113891883A (zh) * 2019-03-29 2022-01-04 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
WO2020205481A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
CN113939507A (zh) * 2019-03-29 2022-01-14 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
US20220227722A1 (en) * 2019-04-26 2022-07-21 Receptos Llc Sphingosine 1 phosphate receptor modulator
CN110256288A (zh) * 2019-05-13 2019-09-20 苏州山青竹生物医药有限公司 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2913326B1 (en) 2008-05-14 2020-07-15 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
US8446183B2 (en) 2009-06-25 2013-05-21 Nova Research, Inc. High current emitter drive unit cell
CA2986521C (en) 2009-11-13 2020-06-30 Celgene International Ii Sarl Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Also Published As

Publication number Publication date
IL254679A0 (en) 2017-11-30
AU2016246398A1 (en) 2017-10-26
WO2016164180A1 (en) 2016-10-13
CA2981743A1 (en) 2016-10-13
TW201636336A (zh) 2016-10-16
EP3280703A1 (en) 2018-02-14
US20180016244A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
AR104174A1 (es) Oxadiazoles sustituidos con deuterio
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CO2019003178A2 (es) Compuestos de dinucleótidos cíclicos
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CL2016002348A1 (es) Agonistas del receptor muscarínico
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY37169A (es) Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CR20160419A (es) Nuevos compuestos biciclicos
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
UY37410A (es) Antagonistas de trpv4
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CO2018005753A2 (es) Composición hemostática
BR112017011387A2 (pt) uso de compostos, e, composição cosmética.
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции

Legal Events

Date Code Title Description
FB Suspension of granting procedure